Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study
Katherine Young, C Andrew DeRyke, David W Hilbert, Maria C Losada, Jiejun Du, Amanda Paschke, Luke F Chen · 2026
Read Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study by Katherine Young, C Andrew DeRyke, David W Hilbert, Maria C Losada, Jiejun Du, Amanda Paschke, Luke F Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357288.txt.
Description
Katherine Young is first author on a 2026 PLOS ONE subgroup analysis of a trial in severe lung infection caught during hospital care. Such infections increasingly involve germs that resist carbapenems, a last-line drug class, leaving few options. The study drug adds relebactam to imipenem to shield it from bacterial enzymes.
Within the RESTORE-IMI 2 trial, the authors compared patients whose lung germs resisted imipenem but stayed sensitive to the pairing against those with sensitive germs. Death rates by day twenty-eight were similar in the two groups. New resistance to the pairing emerged during treatment in only three patients. Lab checks described the resistant isolates in detail.
Catalog record
| CREATOR | Katherine Young, C Andrew DeRyke, David W Hilbert, Maria C Losada, Jiejun Du, Amanda Paschke, Luke F Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30043 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |